key: cord-0012978-n1usz03q
authors: Supuran, Claudiu T.
title: Coumarin carbonic anhydrase inhibitors from natural sources
date: 2020-08-11
journal: nan
DOI: 10.1080/14756366.2020.1788009
sha: 161c4616dc742f239bda8f6e515134ba5d8305b3
doc_id: 12978
cord_uid: n1usz03q

Coumarins constitute a relatively new class of inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), possessing a unique inhibition mechanism, acting as “prodrug inhibitors.” They undergo the hydrolysis of the lactone ring mediated by the esterase activity of CA. The formed 2-hydroxy-cinnamic acids thereafter bind within a very particular part of the enzyme active site, at its entrance, where a high variability of amino acid residues among the different mammalian CA isoforms is present, and where other inhibitors classes were not seen bound earlier. This explains why coumarins are among the most isoform-selective CA inhibitors known to date among the many chemotypes endowed with such biological activity. As coumarins are widespread secondary metabolites in some bacteria, plants, fungi, and ascidians, many such compounds from various natural sources have been investigated for their CA inhibitory properties and for possible biomedical applications, mainly as anticancer agents targeting hypoxic tumours.

Coumarins are bicyclic aromatic compounds incorporating two oxygen atoms, an endocyclic and an exocyclic one, forming thus a cyclic lactone, as shown in Figure 1 for the simplest such derivative 1. Due to the presence of the lactone moiety, coumarins are easily hydrolysed, mainly in alkaline conditions, to the corresponding 2hydroxy-cinnamic acid 2as sodium salts (usually as a trans isomer), which in turn, easily recyclizes (in acidic medium) with the formation of the initial coumarin and loss of a water molecule [1] [2] [3] [4] [5] . The chemistry of this well-known class of organic compounds was extensively reviewed and will be not discussed in detail here 1-4 . Coumarins are widespread natural products, being present as secondary metabolites in many species of bacteria, plants, fungi, and marine organisms (such as the ascidians) [3] [4] [5] [6] [7] [8] [9] [10] . They also possess a range of biological activities, the best-known one being that of anticoagulants 11 , although for many representatives (natural or synthetic coumarin derivatives) other pharmacological activities were reported. They include inhibition of the enzyme monoamine oxidase (MAO) 4, 5 , anti-infective activity (as antibacterial, antifungal, and antiviral agents) 8 , antioxidants 2, 8 , antitumor 2, 4 , and anti-inflammatory action 2, 4, 8 , among others. In many cases (except the anticoagulant effects 11 and MAO inhibition 4,5 ) the precise mechanism of action or the real biological targets of the coumarins, active against so many different diseases/conditions, are not clearly understood. A rather different situation on the other hand is encountered for the enzyme carbonic anhydrase (CA, EC 4.2.1.1), for which the inhibitory activity of this class of compounds has been reported a decade ago 6, 7 . Indeed, the first report that a natural product coumarin (compound 3, Figure 1 ) acts as an inhibitor of this enzyme came from Quinn's group 7 who reported a high-throughput screening assay of a large library of natural products of Australasian origin and detected just one active hit, compound 3. However, as coumarins were not among the classical chemotypes known to inhibit these enzymes 12, 13 , only a subsequent detailed study 6 demonstrated that coumarin 3 present in the Australian pant Leionema ellipticum (and coumarins more generally 6,10 ) are indeed a new class of CA inhibitors (CAIs) with a definitely unique inhibition mechanism, the real inhibitor being, in fact, the hydrolysed coumarin derivative, 4 ( Figure 1 ). In the following part of this review, I will examine the natural product coumarins reported to date to possess significant CA inhibitory properties and their potential use as pharmacological agents, after briefly introducing CAs and their inhibition/activation mechanisms. development for the management of metastatic, hypoxic tumours [31] [32] [33] [34] . It should be also noted that recently, some types of CAIs showed promising activity for the management of conditions such as neuropathic pain 35, 36 , cerebral ischaemia 37 , arthritis [38] [39] [40] , idiopathic intracranial hypertension 41 , and some neurodegenerative disorders 42, 43 . On the other hand, the CA activators (CAAs) show pharmacological applications for memory therapy 44 and in the modulation of emotional memory, which opens the possibility to apply them in areas with few therapeutic options at this moment, such as phobias, post-traumatic stress, generalised anxiety, and obsessive-compulsive disorders 45, 46 .

There are at least four CA inhibition mechanisms reported to date 12, [47] [48] [49] [50] , which together with the CA activation mechanism are schematically shown in Figure 2 for a-CAs which incorporate a Figure 1 . The simplest coumarin, compound 1, its hydrolysis product 2, and the natural product coumarin 3 (and its hydrolysis product 4) for which the CA inhibitory activity was first reported 6 . Figure 2 . CA inhibition mechanisms (A-D) and the CA activation mechanism (E). The CA modulators of activity incorporate various scaffolds and tails in their molecule, as well as characteristic functionalities for all category: (A) the zinc binders possess a zinc-binding group (ZBG) which is coordinated to the metal ion; (B) the compounds which anchor to the zinc-coordinated water incorporate an anchoring group (AG) which hydrogen bonds with the water coordinated to the metal and the OH of Thr199; (C) AGs are also present in compounds which occlude the entrance of the active site cavity; (D) some inhibitors which bind out of the active site; (E) the activators incorporate proton-shuttling moieties (PSMs) and bind in the same active site region as the inhibitors shown at (C). Only a-class CAs are considered here (as they are the enzymes present in mammals, including humans 12,14 ) although these mechanisms may be valid to other CA classes. catalytically crucial zinc ion at their active site 12, 14 . They can be classified as follows:

1. Inhibitors acting as zinc binders (Figure 2(A) ). These chemotypes possess a zinc-binding group (ZBG) which is coordinated to the metal ion, whereas the remaining part of their molecule interacts either with the hydrophobic, hydrophilic, or both halves of the active site 12, [47] [48] [49] [50] . Some ZBGs (sulphonamides, sulfamates, sulfamides, carboxylates, hydroxamates, benzoxaboroles, etc.) also participate in hydrogen bond interactions with two amino acid residues conserved in all a-CAs, the socalled gatekeepers, Thr199-Glu106 12 . Their scaffold can be aromatic, heterocyclic, aliphatic, or carbohydrate-based 47-50 . 2. Inhibitors anchoring to the zinc-coordinated water molecule ( Figure 2 (B)). These inhibitors incorporate an anchoring group (AG) in which hydrogen bonds with the water coordinated to the metal ion (acting as a nucleophile in the catalytic reaction), as well as with the OH of Thr199 from the gatekeeper dyad [47] [48] [49] [50] . Phenols, polyamines, sulfocoumarins, and some other compounds inhibit CAs by this mechanism 51, 52 . So, AG is usually an OH, NH 2 , or SO 3 H moieties 47-52 . 3. Inhibitors which occlude the entrance to the active site ( Figure  2 (C)). Coumarins, which will shortly be discussed in detail, are the compounds that bind in this way 6,10,53-55 , rather far away from the metal centre, at the entrance of the cavity. AG is here a COOH or phenolic OH moiety ( Figure 2 (C)). 4. Inhibitors binding out of the active site ( Figure 2 (D)). Only one example of such a derivative is known at the moment (2-benzylsulfonyl-benzoic acid), which binds in an adjacent hydrophobic pocket to the entrance to the active site cavity, blocking the proton shuttle of the enzyme, residue His64 in its out conformation, which leads to the collapse of the catalytic cycle 56 . 5. CA activators (Figure 2 (E)). These modulators of CA activity do not abolish but enhance the catalytic efficiency of these enzymes, which are already highly effective catalysts for the CO 2 hydration reaction 12, 14, 46 . The CA activators incorporate proton-shuttling moieties (PSMs) in their molecules, which most of the time are of the amino, carboxylate, or imidazole type [57] [58] [59] [60] and bind at the entrance of the active site cavity. Thus, the activator binding site is superimposable with the coumarin-binding site shown in Figure 2 (C) [57] [58] [59] [60] .

Nowadays, a huge number of various chemotypes are associated with the inhibition and activation of CAs, and as mentioned above some of these compounds are clinically used as drugs for the management of a variety of disorders 12, 14, 15, [21] [22] [23] [24] [25] [26] [27] [28] [29] 33 . However, as in humans, there are 15 CA isoforms which are rather similar from the structural viewpoint 12, 14 , for a very long period it was considered impossible to obtain isoform-selective CAIs 12 . In fact, the quite large number of disorders in which inhibitors and activators of CAs show pharmacological effects is in fact due to the large number of isoforms, their diverse sub-cellular and tissue distributions, which leads to very different functions of the many CA isoforms present in various cells/tissues/organs 12, 14, 15, [21] [22] [23] [24] [25] [26] [27] [28] [29] 33 . Thus, the first and second generation CAIs, which all belong to the zinc binders and are sulphonamides, sulfamates, and sulfamides, are in fact still in clinical use, but they are associated with relevant side effects due to their non-isoform selective profiles and off-target inhibition 12, 14, 15, [21] [22] [23] [24] [25] [26] [27] [28] [29] 33, 61 . Only the discovery of coumarins as CAIs 6,7 allowed for the first time the rational drug design of isoform-selective inhibitors for all the catalytically active human(h) CA isoforms (12 of the 15 hCA isoforms possess catalytic activity, whereas hCA VIII, X, and XI are devoid of it 12, 14 ) As shown in Figure 2 (C), these compounds, the coumarins, bind at the entrance of the hCA active site, which is the region most variable between the different isoforms 12, 14 . For this reason, compounds which can bind and interact with amino acid residues in this part of the active site are generally characterised by an enhanced isoform-selectivity compared with compounds which bind deep within the active site, where a large number of the amino acid residues are conserved among the various CA isoforms 12,14,16 .

Detailed kinetic and X-ray crystallographic techniques allowed us to unravel the CA inhibition mechanism with coumarins 6,10 . The first crystal structure was that of the natural product coumarin 3 6 bound to human (h) isoform hCA II, followed shortly thereafter by the crystal structure of the simple coumarin 1 (Figure 1 ) bound to the same isoform 10 . These two X-ray crystallographic structures are superimposed in Figure 3 .

Coumarins possess unique characteristics as CAIs, as determined from kinetic, mass spectrometric, and crystallographic experiments 6, 10 . Unlike sulphonamides or other small molecule inhibitors, the formation of the enzyme-inhibitor complex is not a rapid process 16 , but it takes several hours 6 . Indeed, all experiments for determining the inhibition constants of these compounds are done by incubating the enzyme and the coumarins for 6 h 6,10 , whereas for other classes of CAIs the incubation period is 15 min 10, 14 . This was the first indication that probably the coumarins are suicide inhibitors, which in fact was confirmed by the crystallographic experiments 6, 10 . As seen from Figure 3 , the coumarin ring is not present in the enzyme-inhibitor complexes formed between hCA II and the coumarins 1 and 3, respectively. Instead, the corresponding hydrolysis products, 2-hydroxy-cinnamic acids 2 and 4 are observed bound at the entrance of the active site. This can only be achieved by the hydrolysis of the lactone ring of the coumarins through the esterase activity of hCAs, which in fact has Figure 3 . X-ray crystal structure of adducts of coumarins 1 10 and 3 6 bound to hCA II. The hydrolysis products of the two coumarins, cis-2-hydroxycinnamic acid 2 (in yellow) and trans-2-hydroxy-cinnamic acid 4 (in magenta) were observed bound wat the entrance of the CA active site. The catalytic Zn(II) ion is the central violet sphere, its three protein ligands (His94, 96 and 119, CPK colors) and the proton shuttle residue His64 (in red) are evidenced. The hCA II backbone is shown as the green ribbon, with its various a-helices, b-sheets, and loops represented in a canonical manner. been well documented earlier [62] [63] [64] . It is interesting to note that the unsubstituted 2-hydroxy-cinnamic acid 2 binds to the enzyme in its trans geometry, whereas the much bulkier derivative 4 obtained from the natural product coumarin 3 was observed in the generally less stable cis geometry (Figure 3 ). But the most relevant finding was that these compounds bind at the entrance of the active site cavity at around 8-10 Å from the zinc ion 6, 10 . In this active site region, no other inhibitors were observed bound previously, confirming the uniqueness of the coumarin inhibition mechanism. Thus, coumarins are indeed suicided CAIs, which undergo hydrolysis through the esterase CA activity and bind in a region of the active site not exploited by other classes of inhibitors, but which is in fact the same binding site of the CA activators 46,59,60 . This discovery led to a large number of studies of coumarins as CAIs, both synthetic and naturally occurring derivatives.

The most extensive study of natural product coumarins (NPCs) acting as CAIs was reported by Davis et al. 9 who investigated a series of such derivatives (Figure 4 ) isolated from plants and ascidians, of types 5-35, for the inhibition of six hCAs (Table 1) . Isoforms hCA I, II, VII, IX, XII, and XIII were investigated. The first three of them and hCA XIII are cytosolic enzymes, whereas hCA IX and XII are transmembrane, tumour-associated isoforms, present in few normal tissues 12, 14, 16 and validated as antitumor drug targets 21 . The NPCs incorporate a variety of scaffolds, as shown in Figure 4 , ranging from very simple coumarins with compact substituents, such as those present in 11, 12, 14, 17, 33, etc. , to rather complex/bulky substituents in various positions, or condensation with other ring systems, such as in 5-7, 19, 20, 24, 25, 26, 34, 35, etc. As seen from data of Table 1 , all types of activities were observed with coumarins 5-35, but most of the derivatives were inactive or showed poor activity against the house-keeping and most diffuse isoform, hCA II, whereas they acted as efficient, micro-or submicromolar inhibitors against the other isoforms, such as hCA I, VII, IX, XII and XIII. One compound (17) was a low nanomolar inhibitor of hCA I (Table 1) . Generally, hCA IX and XII showed better inhibition with these NPCs compared to the other isoforms 9 . As for all other coumarins investigated to date 6,10 , nature and position (number) of substituents on the coumarin ring were the most important factors influencing the enzyme inhibitory properties of these compounds 9 .

Another, more recent study, by Fois et al. 65 reported coumarins from the Sardinian plant Magydaris pastinacea ( Figure 5 ) acting as efficient inhibitors of the tumour-associated isoforms hCA IX and XII whereas their activity for the cytosolic isoforms hCA I and II was found to be very weak ( Table 2) .

Some of these compounds (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) are in fact variously substituted furo-coumarins (psoralens), with a tricyclic ring system incorporating the furan heterocycle, and this class of NPs is well known in nature, being present in many other plants 65 . The remaining derivatives incorporate isoprenyl-, hydrated isoprenyl-or polyprenylated moieties, also typical for many NPs 65 . It is interesting to note that all coumarins/furocoumarins 36-45 were ineffective as hCA I and II inhibitors, whereas they showed a rather good, high nanomolar inhibitory action against the tumour-associated isoforms hCA IX and XII (Table 2) 65 .

In another study, by Melis et al. 66 , several other NP coumarins and psoralen derivatives (51) (52) (53) (54) (55) (56) (57) (58) , this time incorporating carboxylic acid or ester moieties, were investigated as CAIs against isoforms hCA I, II, IX, and XII (Table 3 ). There is a continuous interest in this class of derivatives for their potential applications as antifungal agents 67 or photo-activatable antitumor drugs, due to the photochemical properties of the psoralen ring system 68 .

As for the derivatives from Magydaris pastinacea, also these investigated coumarins/psoralens 51-58 showed no inhibitory action towards the cytosolic hCA I and II isoforms, which is a positive feature, as these are house-keeping enzymes in most cells/ tissues, but they were effective, in some cases as low nanomolar inhibitors against the tumour associated isoforms hCA IX and XII; making them of interest for anticancer studies. In fact, already in 2011, our group demonstrated 69 that some synthetic (not NP) coumarins incorporating glycosyl moieties show very effective in vitro CA IX/XII inhibitory action (with no inhibition of the off-target isoforms hCA I and II) and also a significant antitumor and antimetastatic effects in an in vivo animal model of hypoxic, metastatic tumours 70 .

Due to their unique CA inhibition mechanism, coumarins, and related compounds afforded for the first time the advent of highly isoform-selective CAIs for all human isoforms among the 12 catalytically active ones. The NP coumarins were essential for unravelling the inhibition mechanism and also for understanding in detail the structure-activity relationship for this class of enzyme inhibitors. Due to their particular inhibition mechanism, the presence of The standard sulphonamide inhibitor acetazolamide (AAZ) is also included. bulky moieties in the 3 position of the coumarin ring is associated with very poor or no CA inhibition. As a consequence, all the anticoagulant coumarins, which do possess very bulky moieties in position 3, do not act as CAIs, which is a positive feature both for the coumarin CAIs eventually designed for various pharmacological applications, as well as for the anticoagulants. Apart from their highly interesting features as isoform-selective inhibitors, the discovery of coumarins as CAIs stimulated the research for the discovery of new chemotypes possessing such properties or similar inhibition mechanisms. Indeed, the monocyclic 5-and 6-ring lactones and thiolactones were reported to possess CA inhibitory effects 71 , as well as thio-and 2-thioxocoumarins 72 , quinoline-2-ones 73 , sulfocoumarins 74 , homosulfocoumarins 75, 76 and various hetero-coumarins incorporating selenium, tellurium and other elements 77 . More recently, this type of prodrug CAI inspired also other groups to investigate this type of suicide inhibitor, such as for example aspirin, reported by McKenna's group 78 . The huge number of synthetic studies of non-NP coumarins which have been reported in the last decade are not mentioned here, but many such compounds have been designed and showed a relevant biological activity. Overall, the very interesting moieties present in the NP coumarins make them a source of inspiration for medicinal chemists and pharmacologists in the search of new drugs with a safer profile and specific action in a variety of disorders, starting from the infective ones 79 and ending with tumours 80 and inflammatory diseases 81 . For the moment, only the human a-CAs were investigated for their inhibition profile with coumarins, but such enzymes are also present in other organisms, such as pathogenic bacteria, protozoans, and fungi 82-85 . Investigation of coumarin derivatives (including NPCs) against these enzymes may thus lead to interesting developments in the fight of infections produced by such pathogens.

No potential conflict of interest was reported by the author(s). 

The chemistry of coumarins

Coumarins: old compounds with novel promising therapeutic perspectives

Coumarin compounds in medicinal chemistry: some important examples from the last years

Coumarin: a natural, privileged and versatile scaffold for bioactive compounds

MAO inhibitors and their wider applications: a patent review

Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors

Direct screening of natural product extracts using mass spectrometry

Translational role of natural coumarins and their derivatives as anticancer agents

Natural product coumarins that inhibit human carbonic anhydrases

Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins

Current and emerging direct oral anticoagulants: state-of-the-art

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

In)organic anions as carbonic anhydrase inhibitors

Carbon-versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?

Structure and function of carbonic anhydrases

Biomedical applications of prokaryotic carbonic anhydrases

Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery

Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases

An overview of the bacterial carbonic anhydrases

An overview of the alpha-, betaand gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?

Bacterial i-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii

Carbonic anhydrases and metabolism

Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors

Interfering with pH regulation in tumours as a therapeutic strategy

Designing of novel carbonic anhydrase inhibitors and activators

Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases

Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies

Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases

Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste

Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas

The management of glaucoma and macular degeneration

Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019

The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies

Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review

Antiobesity carbonic anhydrase inhibitors: a literature and patent review

N-aryl-N 0 -ureido-O-sulfamates as potent and selective inhibitors of hCA VB over hCA VA: deciphering the binding mode of new potential agents in mitochondrial dysfunctions

Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one

A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors

Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review

Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia

Carbonic anhydrase inhibition and the management of neuropathic pain

A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects

Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors

Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium

Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis

Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis

Acetazolamide for the treatment of idiopathic intracranial hypertension

The carbonic anhydrase inhibitor methazolamide prevents amyloid betainduced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain

A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer's disease

Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signalregulated kinase in the cortex and the hippocampus

Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders

Carbonic anhydrase activators

Activation of a-, b-, c-d-, f-and g-class of carbonic anhydrases with amines and amino acids: a review

Advances in structure-based drug discovery of carbonic anhydrase inhibitors

How many carbonic anhydrase inhibition mechanisms exist?

Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors

Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery

Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV))

Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxybromophenol derivatives incorporating cyclopropane moieties

Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms

Coumarins incorporating hydroxyand chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II

8-Disubstituted-but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range

Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX

Out of the active site binding pocket for carbonic anhydrase inhibitors

Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine1

Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII

Activation effects of carnosine-and histidine-containing dipeptides on human carbonic anhydrases: a comprehensive study

The coumarinbinding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors

An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of a-but not of b-, c-and f-carbonic anhydrases

Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates

a-carbonic anhydrases possess thioesterase activity

Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic anhydrases IX and XII: isolation, biological studies and in silico evaluation

Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors

A prodrug approach to the use of coumarins as potential therapeutics for superficial mycoses

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis

Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors

5-And 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors

Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins

7-Amino-3,4-dihydro-1H-quinolin-2-one, a compound similar to the substituted coumarins, inhibits a-carbonic anhydrases without hydrolysis of the lactam ring

Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases

3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors

Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/ XII and of human thioredoxin reductase

Heterocoumarins are selective carbonic anhydrase IX and XII inhibitors with cytotoxic effects against cancer cells lines

Aspirin: a suicide inhibitor of carbonic anhydrase II

A deadly spillover: SARS-CoV-2 outbreak

The carbonic anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells

Coxibs and cardiovascular side-effects: from light to shadow

Anti-Helicobacter pylori activity of ethoxzolamide

Sulphonamide inhibition studies of the b-carbonic anhydrase from the bacterial pathogen Clostridium perfringens

Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695

The first activation study of the b-carbonic anhydrases from the pathogenic bacteria Brucella suis and Francisella tularensis with amines and amino acids

(b) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents

Bacterial, fungal and protozoan carbonic anhydrases as drug targets

Appraisal of antiprotozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani

Crystal structure and chemical inhibition of essential schistosome host-interactive virulence factor carbonic anhydrase SmCA